Back

Evaluating risk factors, biomarkers and management of myocarditis following treatment with checkpoint inhibitors. A retrospective analysis.

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: National registries for rare myocardial diseases Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Mustafa Omar Abdimalik

Liverpool Heart and Chest Hospital, Liverpool (United Kingdom of Great Britain & Northern Ireland)

7 More presentations in this session

Presentation thumbnail
Trends in the prevalence of infiltrative cardiomyopathy among patients with in-hospital cardiac arrest- insight from the US national inpatient sample database
Doctor S. Nandy (Bronx, US)
Abstract Slides
Presentation thumbnail
HCM-AF South Italy score for prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy: data from a derivation and validation italian cohorts.
Doctor G. Todde (Naples, IT)
Abstract Slides
Presentation thumbnail
Population estimates of obstructive and non-obstructive hypertrophic cardiomyopathy in the UK and Germany
Doctor M. Tome Esteban (London, GB)
Abstract Slides
Presentation thumbnail
Genetic and clinical characteristics of transthyretin cardiac amyloidosis in Koreans
Doctor K. Jeon (Seoul, KR)
Abstract Slides
Presentation thumbnail
Cardiomyopathy and cardiovascular events by gender in a comprehensive Finnish patient population with Fabry disease
Doctor K. Valtola (Kuopio, FI)
Abstract Slides

Access the full session

Session thumbnail
National registries for rare myocardial diseases

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources